Here's Why HealthEquity (HQY) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 2, 2026

BLCO vs. HQY: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 23, 2026

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

Zacks Investment Research • Jan 19, 2026

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jan 15, 2026

HealthEquity, Inc. (HQY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

HealthEquity, Inc. (HQY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

The Market's Not Diagnosing HealthEquity Accurately

HealthEquity remains a 'buy' despite a 10.2% drop after 2027 guidance disappointed the market. HQY's core HSA business continues robust account and asset growth, driving consistent revenue and profit expansion. Management projects 2027 revenue of $1.38–$1.41 billion and EBITDA margins of 43.8–44.3%, supporting a bullish outlook.

Seeking Alpha • Jan 14, 2026

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.

Zacks Investment Research • Dec 31, 2025

HealthEquity (HQY) Moves to Buy: Rationale Behind the Upgrade

HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 10, 2025

Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think "Yes"

HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Dec 10, 2025

HealthEquity Stock Gains as Q3 Earnings Beat Estimates, Revenues Up Y/Y

HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.

Zacks Investment Research • Dec 4, 2025